Stimulus Hopes Rise...
Health Care: Drugs
Abbott Laboratories (ABT: NYSE)
$60.22 -0.30 | -0.50%
06/04/12 - 04:02 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 38.85B | 35.17B | 30.76B | 29.53B |
| Cost of Sales | 12.50B | 12.04B | 11.12B | 10.77B |
| Gross Operating Profit | 26.35B | 23.13B | 19.64B | 18.75B |
| Selling, General, and Administrative Expenses | 12.76B | 10.38B | 8.41B | 8.44B |
| Research & Development | 4.13B | 4.04B | 2.74B | 2.69B |
| Operating Income before D & A (EBITDA) | 9.47B | 8.71B | 8.50B | 7.63B |
| Depreciation & Amortization | 3.04B | 2.62B | 2.09B | 1.84B |
| Interest Income | 85.20M | 105.45M | 137.78M | 201.23M |
| Other Income - Net | -108.36M | 72.94M | 1.34B | 370.70M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | 5.73B | 6.27B | 7.71B | 6.38B |
| Interest Expense | 530.14M | 553.14M | 519.66M | 528.47M |
| Pre-Tax Income | 5.20B | 5.71B | 7.19B | 5.86B |
| Income Taxes | 470.19M | 1.09B | 1.45B | 1.12B |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | 4.73B | 4.63B | 5.75B | 4.73B |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 146.50M |
| Net Income From Total Operations | 4.73B | 4.63B | 5.75B | 4.88B |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 4.73B | 4.63B | 5.75B | 4.88B |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
5.40B | 4.63B | 5.92B | 4.83B |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 4.73B | 4.63B | 5.75B | 4.73B |
| Basic EPS from Continuing Ops. | 3.03 | 2.98 | 3.71 | 3.06 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.10 |
| Basic EPS from Total Operations | 3.03 | 2.98 | 3.71 | 3.16 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 3.03 | 2.98 | 3.71 | 3.16 |
| Basic Normalized Net Income/Share | 3.46 | 2.98 | 3.82 | 3.12 |
| EPS fr Continuing Ops. | 3.01 | 2.96 | 3.69 | 3.03 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.09 |
| EPS fr Total Ops. | 3.01 | 2.96 | 3.69 | 3.12 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 3.01 | 2.96 | 3.69 | 3.12 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
3.44 | 2.96 | 3.80 | 3.09 |
| Dividends Paid per Share | 1.88 | 1.72 | 1.56 | 1.41 |
Portfolios with ABT
- Portfolio NameUser Type
- ContributorRocket Stocks for the Week ...
- Contributor10 Best-Performing 'Dividen...
- Contributor3 Upcoming Spinoffs That Co...
- UserBen's Growth Dividend Stocks
- Userlj's Portfolio
- UserPerpetual growers
- UserEyeon
- UserStock
- Userdiz
- ContributorHighest-Yielding Drug Stocks
Latest ABT Headlines from TheStreet
- 5 Rocket Stocks to Buy in June 06.04.12 | 11:06 am
- 3 Stocks I Saw on TV, June 4
06.04.12 | 08:06 am - Cramer's 'Mad Money' Recap: Europe's Problems a Global Problem 06.01.12 | 07:06 pm
- Abbott Laboratories (ABT): Today's Featured Health Care Loser 06.01.12 | 05:06 pm
- Cramer's 'Mad Money' Recap: Avoid These High-Drama Stocks! 05.30.12 | 08:05 pm
- Cramer on Retirement: Individual Stocks Are Right for Your 401(k) 05.29.12 | 06:05 am
- Abbott Laboratories (ABT): Today's Featured Drugs Loser 05.23.12 | 05:05 pm
- Abbott Laboratories (ABT): Today's Featured Health Care Winner 05.16.12 | 04:05 pm
- Abbott Helps Big Pharma Look Even Worse 05.16.12 | 01:05 pm
- Abbott Laboratories (ABT): Today's Featured Health Care Loser 05.09.12 | 05:05 pm
Press Releases for ABT
- Abbott Again Recognized As One Of The 'Best Places To Work In Industry' By The Scientist Magazine - PR Newswire 06.01.12 | 09:06 am
- Absolute Software Partners With InComm To Sell LoJack For Laptops Through Major U.S. Retailers - PR Newswire 05.31.12 | 07:05 am
- Abbott To Present At Goldman Sachs 33rd Annual Global Healthcare Conference - PR Newswire 05.29.12 | 09:05 am
- Abbott To Present Wide Range Of Investigational Efficacy, Safety And Health Outcomes Data On HUMIRA® (Adalimumab) At The Annual Meeting Of The European League Against Rheumatism - PR Newswire 05.29.12 | 01:05 am
- Absolute Software Awarded Lenovo Top Supplier Award - PR Newswire 05.16.12 | 07:05 am
- Absolute Software Releases Turnkey BYOD Support For All Apple, Android And Windows Mobile Devices, Including Laptops - PR Newswire 05.15.12 | 08:05 am
- Abbott's XIENCE PRIME⢠And XIENCE V® Drug Eluting Stents Receive Indication In Europe For Minimum Three-Month Duration Of Dual Anti-Platelet Therapy - PR Newswire 05.15.12 | 08:05 am
- Abbott's New FreeStyle InsuLinx Blood Glucose Monitoring System With Insulin Calculator Now Available In Canada - PR Newswire 05.10.12 | 01:05 am
- Absolute Software Reaches Favourable Settlement Agreement In Precedent Setting Anti-Theft Patent Infringement Case - PR Newswire 05.08.12 | 06:05 pm
- Grant & Eisenhofer Represents Lead Whistleblower In Historic $1.6 Billion Settlement With Abbott Laboratories Over Off-Label Marketing Of Antiepileptic Medication Depakote - PR Newswire 05.07.12 | 02:05 pm
Partner Headlines for ABT
- Healthcare Business Recap: Dendreon BOMBS, Cancer Cures Galore - Wall St. Cheat Sheet 06.04.12 | 06:06 am
- Watchdog: Cramer Tells Investors Buy These 5 Stocks Now! - Wall St. Cheat Sheet 05.31.12 | 09:05 am
- 5 Strong Companies That Increased Yields By More Than 10% Over The Past 3 Years - Seeking Alpha 05.30.12 | 09:05 am
- Mason Hawkins' Southeastern Discusses Abbott Labs - GuruFocus 05.23.12 | 04:05 pm
- Zacks' Voice of the People highlights opportunities with Johnson & Johnson, Disney, Abbott Labs and Church & Dwight - Press Releases - Zacks 05.23.12 | 09:05 am
- Health Care SPDR In Focus Ahead Of Obamacare Decision - Benzinga 05.22.12 | 12:05 pm
- Auxilium-Glaxo to Drive Testim Sales - Analyst Blog - Zacks 05.22.12 | 10:05 am
- Big-Cap Leaders Bland, But Their Charts Holding Up - Investor's Business Daily 05.21.12 | 07:05 pm
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
